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RÉSUMÉ 
 
Nous avons investigué la relation entre les polymorphismes de nucléotides simples (SNPs) chez 
trois gènes/loci candidats : DARC, CXCL2 et le loci ORMDL3-GSDMA-CSF3 situés sur le 
chromosome 17q21 et les complications neutropéniques et infectieuses qui en résultent durant la 
chimiothérapie chez les patients atteints de la leucémie lymphoblastique aigue. Ces loci codent 
pour certaines composantes du système immunitaire altérant la concentration de chémokines et leur 
distribution (DARC), stimulant le relâchement et la migration des neutophiles de la moelle épinière 
(CXCL2) et régulant la prolifération et la survie des granulocytes (G-CSF). Il est possible que des 
polymorphismes dans ces loci lorsqu’associés à de la chimiothérapie puissent mettre des individus 
suceptibles à un risque plus élevé de complication reliées à la chimiothérapie. Une sélection des 
marqueurs SNPs dans ces gènes ont été génotypés chez des enfants traités au CHU Ste-Justine pour 
une ALL entre 1989 et 2005. Après correction pour tests multiples, un polymorphisme DARC 
rs3027012 situé dans le 5’UTR a été associé à un compte phagocytaire peu élevé (APC<500 et 
<1000 cellules/µL, p=0.001 and p=0.0005, respectivement) ainsi qu’une hospitalisation due à une 
neutropénie (p=0.007) ou  due à une infection et/ou neutropénie  (p=0.007). Un effet protecteur a 
été identifié pour la mutation non sense Gly42Asp variant rs12075 (p=0.006). Des polymorphismes 
sur le chromosome 17q2 étaient associés à une hospitalisation due à une infection (rs3859192, p= 
0.004) et à une neutropénie (rs17609240, p=0.006) L’infection était aussi modulée par CXCL2 
(rs16850408, p=0.008) Cette étude identifie pour la première fois que les loci modulant le 
décompte des leucocytes et des neutrophiles pourraient jouer un rôle dans de déclenchement de 
complications dues à la chimiothérapie et pourraient ainsi servir de marqueurs pour un ajustement 
et un suivi du traitement. 
Mots-clés: polymorphismes génétiques, neutropénie, infection, leucémie lymphoblastique aigue 
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ABSTRACT 
 
We investigated the relationship between single nucleotide polymorphisms (SNPs) in 3 candidate 
genes/chromosomal loci: DARC, CXCL2 and ORMDL3-GSDMA-CSF3 locus on chromosome 
17q21, and neutropenic and infectious complications during chemotherapy in pediatric acute 
lymphoblastic leukemia (ALL) patients. These loci encode the components of immune system 
altering chemokine concentration and distribution (DARC), stimulating neutrophil release from 
bone marrow and migration (CXCL2) and regulating granulocyte proliferation and survival (G-
CSF). It is possible that polymorphisms of these loci when associated with chemotherapy may put 
susceptible individuals at higher risk of chemotherapy complications. Selected tag SNPs in these 
genes are genotyped in children treated at the CHU Sainte-Justine for (ALL) between 1989 and 
2005. After correction for multiple testing, DARC polymorphism rs3027012 in 5’UTR was 
associated with low absolute phagocyte count (APC<500 and <1000 cells/µL, p=0.001 and 
p=0.0005, respectively) and hospitalisation due to febrile neutropenia (p=0.007) or due to infection 
and/or febrile neutropenia (p=0.007). A protective effect was instead noted for missense Gly42Asp 
variant rs12075 (p=0.006). The polymorphisms on chromosome 17q2 were associated with 
hospitalisation due to infection (rs3859192, p= 0.004) and neutropenia (rs17609240, p=0.006). 
Infection was also modulated by CXCL2 (rs16850408, p=0.008) This study identifies for the first 
time that the loci modulating white blood cell and neutrophil count may play a role in the onset of 
chemotherapy complications and may thus serve as markers for adjustment or follow-up of the 
treatment.  
 
. Keywords: genetic polymorphisms, neutropenia, infection, acute lymphoblastic leukemia,  
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CHAPTER 1: INTRODUCTION 
 
A. Acute Lymphoblastic Leukemia (ALL) 
A.1. Introduction to ALL 
Pediatric cancers affect approximately 1 in 500 children before the age of 15 years and are the 
leading cause of death by disease in this population.   
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer (26%) and the main 
type of leukemia. ALL accounts for 80% of childhood leukemia [Ward et al., 2014] Leukemia is 
a biologically and clinically heterogeneous disease of the blood cells with many different types 
and subtypes. The important characteristics of acute leukemia is the rapid growth of abnormal 
white blood cells that accumulate in the bone marrow and interfere with the production of normal 
blood cells. 
The acute leukaemia is divided by morphological and cytochemical criteria into myeloid and 
lymphoid subtype. For acute leukemia, the flow cytometry is the method of choice for determining 
the blast lineage that has been affected. 
Lymphoid malignancies can be classified by cell surface antigen phenotype as derived from either 
T or B cell lineage [Amylon et al., 1999]. Further, ALL has been classified into precursor T, 
precursor B, and B-cell (Burkitt) phenotypes, which are then further subdivided according to 
recurrent karyotypic abnormalities, including aneuploidy and translocations. 
T-acute lymphoblastic leukemia (T-ALL) is a neoplasm of immature T-cell precursors or 
lymphoblasts and accounts for 10% to 15% of newly diagnosed cases of childhood acute 
lymphoblastic leukemia (ALL) [Onciu, 2009]. Historically, T-ALL patients have had a worse 
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prognosis than other ALL patients. Patients with T-ALL remain at increased risk for induction 
failure, early relapse, and isolated CNS relapse [You et al., 2015].  
In about 80% to 85% of children with ALL, the leukemia starts in B cells. There are several 
subtypes, and the most common is precursor B-cell (B-lymphoblastic) leukemia. Children 
diagnosed with B-precursor ALL have a good prognosis [Smith et al., 1996]. 
Mature B-cell ALL (also called Burkitt leukemia) is rare, accounting for only about 2% to 3% of 
childhood ALL [Meinhardt et al., 2010]. 
Acute myeloid leukemia (AML) is the second-most common form of leukemia in children.  AML 
comprises almost 20% of pediatric leukemia [Ries et al., 1999]. 
In the World Health Organization (WHO) classification, the term “myeloid” includes all cells 
belonging to the granulocytic (neutrophil, eosinophil, basophil), monocyte/macrophage, erythroid, 
megakaryocytic and mast cell lineages.  A minority of children have ambiguous or mixed lympho-
myeloid phenotypes [Vardiman et al., 2009]. 
ALL could affect children of all ages, however the highest incidence is seen between ages 2 and 5 
years [Pui et al., 1998]. The incidence in children under the age of five years old was 5.7 per 
100,000 person years, followed by the 5- to 9-years old (2.7) and the 10- to 14-years old (1.6)  
[Siesling et al., 2003]. 
 
A.2. Etiology of ALL   
Epidemiological studies of leukemia have examined a number of possible risk factors 
(environmental, genetic, and infectious) in an effort to determine the etiology of the disease. 
Various factors have been reported to confer an increased risk for this disease, including high birth 
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weight, parental occupation, maternal reproductive history, parental tobacco or alcohol use, 
maternal diet, exposure to pesticides or solvents and exposure to the highest levels of residential, 
power-frequency magnetic field [Hjalgrim et al., 2003; Buckley et al., 1989; Infante-Rivard et al., 
2005]. 
Recent studies have also suggested that early exposure to infection may be protective to childhood 
ALL [Urayama et al., 2011]. To date, however, no direct gene-environment interactions have been 
established convincingly.  
Certain genetic conditions as Down syndrome, Bloom syndrome and ataxia-telangiectasia are 
associated with an increased risk for acute leukemia. [Fung et al., 1987; Taylor et al., 1996]. 
A higher risk exists for other less common chromosomal abnormalities including Klinefelter's 
syndrome, trisomy G, neurofibromatosis, and Schwachmann's syndrome [Margolin et al., 2002]. 
There are a number of constitutional chromosomal abnormalities associated with childhood 
leukemia. Chromosomal abnormalities and translocation could have an important role in the 
genesis of leukemia, and they also have prognostic and therapeutic implication. All patients with 
ALL can be classified according to specific genetic abnormalities (Fig A). [Pui et al., 2012]. 
Recurrent chromosomal abnormalities are a hallmark of lymphoblastic leukemia. The most 
common translocation found in childhood B-precursor ALL is the t(12;21)(p13;q22). The presence 
of this translocation has been demonstrated in approximately 25% of childhood ALL [Yeoh et al., 
2002]. The TEL-AML1 fusion protein generated by the t(12;21) contains the basic helix-loop-
helix domain of TEL, fused to the DNA-binding and transactivation domains of AML1. Both the 
TEL and AML1 genes are found in other leukemia-associated translocations. TEL-AML1 
expression is associated with an excellent prognosis, with event-free survival rates approaching 
90% [Rubnitz et al., 1999]. 
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Another common chromosomal aberration found in B-precursor ALL is the presence of more than 
46 chromosomes (hyperdiploid ALL). Patients with this aberration have a very good prognosis 
with event-free survival rates near 90%. 
The t(1;19)(q23;p13) encoding the E2A-PBX fusion protein is present in about 6% of all B-
precursor leukemia. 
The most chromosomal translocations in T-ALL patients lead to inappropriate activation of 
structurally intact cellular proto-oncogenes such as MYC, TAL1, HOX11 or LMO2. Although some 
translocations can produce fusion genes. MLL-ENL fusion results from the translocation 
t(11;19)(q23;p13), and is associated with AML, B-cell precursor ALL, and T-ALL. The 
translocation encoding the BCR-ABL fusion protein is found in only 5% of childhood cases [Pui 
et al., 1995]. 
 
A.3. Prognostic factors 
The treatment of childhood acute lymphoblastic leukemia has advanced significantly over the past 
3 decades, with overall survival rates progressing from 20% to 75%. The identification of biologic 
and clinical prognostic factors allowed the definition of patient subgroups with distinct relapse 
risks and the realization of risk-adapted treatment strategies. This improvement can be attributed, 
in part, to “risk-adapted therapy”. Risk is defined based on clinical and biologic variables, 
cytogenetic and immunophenotypic characteristic of leukemic cells. Treatment intensity is then 
modified according to expected event- free survival (EFS) to maximize cure while minimizing 
toxicity [Silverman et al., 2010]. 
Age at diagnosis, WBC count, gender, and DNA index have strong prognostic effect. Age and 
WBC count are ideal parameters as these are always available. Therefore, in the classification of 
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the National Cancer Institute, standard risk (SR) is defined as age 1-9 years old and WBC 
<50,000/µL and high risk (HR) as WBC >50,000/µL or/and age 10 years and more. 
DNA index >1.16 and hyperdiploidy (>50 chromosomes per leukemic cell) is associated with more 
favorable outcome. Overall survival (OS) in girls is more favorable than with boys. 
African-American and Hispanic children with ALL tend to have a lower cure rate than children of 
other races.   
Primary genetic abnormalities can be identified in 75% to 80% of childhood ALL cases with 
standard chromosomal and molecular genetic analyses. Molecular screening for fusion genes and 
cytogenetics at diagnosis are useful methods to identify some of the high risk patients.   
Hyperdiploidy, TEL-AML1 fusion, and trisomy 4, 10 and 17 are associated with favorable 
prognosis, whereas the Philadelphia chromosome, t(4;11), and hypodiploidy, MLL 
rearrangements and fusion genes the E2A-PBX have less favorable outcome [Pui et al., 2012]. 
The MLL gene (also termed ALL-1, HRX, and TRX1) located at chromosome band 11q23 is a 
recurrent target of chromosomal translocations in acute leukemias.  
Rearrangements of the MLL gene occur in both acute lymphoblastic and acute myeloid leukemia 
and are associated with aggressive acute leukemias.  
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Figure A. Estimated frequency of specific genotypes in childhood ALL [Pui et al., 2012]. 
 
A.4. Treatment of ALL 
Progress in the treatment of patients with ALL has led to better survival rates, but children have 
benefited more from improved treatment than adults. The prognosis in children with ALL is one 
of the most favourable of all disseminated cancers: more than 95% achieve complete remission 
(CR) and disease-free survival rates (5 years) are 63 to 83%. 
The rate of success in the treatment of ALL has increased steadily since the 1960s. The five-year 
event-free survival rate is nearly 80 percent for children with ALL [Pui et al., 2004]. In the United 
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States, ALL is more common in boys than in girls and Hispanic and white than black children 
[Ward et al., 2014]. 
Progress has been incremental, from the introduction of combination chemotherapy and central 
nervous system treatment for pre symptomatic leukemia to newer, intensive treatment regimens 
for patients at high risk for relapse.  
Patients enrolled in our study underwent treatment with Dana Farber Cancer Institute Consortium 
protocols DFCI 87-01, 91-01, 95-01 and 2000-01. At the time of diagnosis, all patients were 
classified as standard or high risk based upon their presenting features, including age, white blood 
cell (WBC) count, immunophenotype and presence or absence of CNS leukemia. In general, each 
protocol consisted of four phases: Induction (4 weeks), Central Nervous System therapy (3 weeks), 
Intensification (30 weeks), and Continuation therapy (74 weeks). 
Induction Therapy: All patients received multi-agent remission induction to eradicate more than 
99 percent of the initial number of leukemia cells and to restore normal hematopoiesis. This 
treatment phase almost always includes the administration of a glucocorticoid (prednisone, 
prednisolone, or dexamethasone), vincristine, and at least one other agent (usually asparaginase, 
an anthracycline, or both). Children with high-risk or very-high-risk ALL receive four or more 
drugs during remission-induction therapy.  
CNS Therapy consists of intrathecal cytarabine instilled immediately after a diagnostic lumbar 
puncture, and triple intrathecal chemotherapy used in all subsequent treatments. Depending on the 
presenting patient characteristics and the CNS status, patients with low-risk disease received 13 to 
18 intrathecal treatments, and patients with standard-risk disease received 16 to 25 intrathecal 
treatments. 
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CNS relapse remains a major obstacle to cure, accounting for 30% to 40% of initial relapses in 
some clinical trials [Bostrom et al., 2003]. 
CNS treatment prevents relapse avoiding cranial irradiation that has been associated with long 
term sequelae [Pui et al., 2006]. 
Intensification (Consolidation) Therapy: When normal hematopoiesis is restored, patients in 
remission become candidates for intensification therapy. Commonly used regimens for childhood 
ALL include high-dose methotrexate with mercaptopurine, high-dose asparaginase given for an 
extended period and corticosteroid. 
Continuation Therapy: Continuation therapy for all patients has included every 3 week cycles of 
vincristine, methotrexate, 6-MP and corticosteroid. Dosing of corticosteroid during intensification 
and continuation therapy has been based upon risk group status, with high risk patients receiving 
3 times the dose of steroids as standard risk patients.  
 
B. Pharmacogenomics 
B.1. Introduction to pharmacogenomics 
Pharmacogenomics is the study of the role of genetics in drug response. The response to 
pharmacologic therapy is characterized by a considerable interindividual variability. Although 
many factors can contribute to variation in response to drug therapy as age, gender, diet, drug 
interactions and nature of the disease, there are now numerous examples of cases in which 
interindividual differences in drug response are due to the variants in genes encoding drug-
metabolizing enzymes, drug transporters, or drug targets. It is estimated that genetics can account 
for 20% to 95 % of variability in drug disposition and effects [Kalow et al., 1998].  
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The interindividual variability of drug response is a major problem in clinical practice and drug 
development [Meyer, 2000]. It can lead to therapeutic failure or adverse effects of drugs in 
individuals or subpopulations of patients. Pharmacogenomics can help to maximize treatment 
efficacy by targeting the use of certain drugs only to patients who will respond appropriately. In 
addition, the use of pharmacogenetics can identify individuals who may be at higher risk of adverse 
side effects of drugs. In such individuals, it is possible to change the treatment modality using a 
different drug or a different drug dose [Krajinovic et al., 2002]. 
The words pharmacogenomics and pharmacogenetics are often used interchangeably. The 
distinction between the two terms has become arbitrary in the literature. 
In general, pharmacogenetics usually refers to how variation in one single gene influences the 
response to a single drug. Pharmacogenomics is a broader term, which studies how all of the genes 
(the genome) can influence responses to drugs. 
 
B.2. Role of pharmacogenomics 
Interindividual differences in drug response could be due to variants in genes encoding drug-
metabolizing enzymes, drug transporters, or drug targets. Subsequently, these variants affect the 
pharmacokinetics or pharmacodynamics of medications and interindividual variability in 
treatment response. Knowing that most drug effects are determined by the interplay of several 
gene products that influence the pharmacokinetics and pharmacodynamics of medications, 
pharmacogenomics research aims to elucidate these polygenic determinants of drug effects. Also, 
polymorphisms in genes encoding proteins that are neither direct targets of medications nor 
involved in their disposition have been shown to alter the response to treatment in certain 
situations. 
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B.2.1. Polymorphisms that influence drug pharmacokinetics 
One important example is the polymorphism of the thiopurine S-methyltransferase (TPMT) gene, 
which encodes the key enzyme in the metabolism of thiopurine. Thiopurine is an essential 
component of treatment for acute lymphoblastic leukemia in children and for intestinal 
inflammatory diseases because of its clinically significant influence on the toxicity of the 
anticancer and immunosuppressive agents: mercaptopurine and azathioprine [Dulucq et al., 2014]. 
These medications are metabolized into active cytotoxic thioguanine nucleotides (TGNs), and 
cytotoxicity occurs mainly by incorporation of TGNs into DNA or RNA resulting in cell cycle 
arrest and apoptosis [Relling et al., 1999]. The most frequent variants are TPMT*2, TPMT*3A and 
TPMT*3C [Cheok et al., 2009; Gervasini et al., 2012]. 
Hematopoietic toxicity risk (myelosuppression) depends on the intracellular concentration of 
TGN, which is inversely proportional to the activity of TPMT. About 30 polymorphisms in the 
TPMT gene have been identified. The most frequent TPMT variants are TPMT * 2 (c.238G> C), 
TPMT * 3A (c.460G> A and c.719A> G), and TPMT * 3C (c.719A> G) [Krynetski et al., 1995; 
McLeod et al., 2000]. Since these three alleles represent over 90% of TPMT inactive alleles, 
genotyping tests have a high probability of being informative. Approximately 10% of the 
population is heterozygous for non-functional variants and accordingly TPMT intermediate 
enzyme activity, while one in 300 inherits two non-functional alleles whereby TPMT has minimal 
enzymatic activity [Cheok et al., 2009]. 
The use of conventional doses of thiopurine in individuals who inherit two inactive alleles of 
TPMT causes severe myelosuppression. A significant proportion of heterozygous individuals will 
show a moderate myelosuppression. Individuals homozygous for the TPMT wild type allele have 
lower concentrations of TGN metabolite and, therefore, present a minor risk of myelosuppression. 
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The existence of numerous studies demonstrating a correlation between TPMT genotype and 
intolerance to 6-MP have prompted the FDA to recommend genotyping for TPMT in patients with 
clinical evidence of myelosuppression. A reduction to 10% of standard dose of 6-MP is 
recommended for individuals who are homozygous for the TPMT variant allele [Relling et al., 
2011]. 
Heterozygous individuals can also benefit from a reduction of the dose. The adjustment of the dose 
based on the genotype of TPMT has reduced side effects induced by thiopurine without 
compromising the anti-tumor effects and immunosuppression [Ansari and Krajinovic, 2007]. 
B.2.2. Polymorphisms that influence drug pharmacodynamics 
During the last 10 years, a number of polymorphisms of genes that encode drug targets have also 
been discovered and shown to alter drug responses.  
Methotrexate (MTX) is an antimetabolite and antifolate agent with antineoplastic and 
immunosuppressant activities. MTX is a key medication for ALL treatment. Many candidate genes 
in the MTX pathway have been studied and shown to impact interindividual differences observed 
in ALL patients. One of the most studied is the thymidylate synthase (TS) gene. TS encodes an 
enzyme which is a key target for the antileukemic role of MTX.  
TS catalyses conversion of deoxyuridylate to deoxythymidylate. Suppression of this enzyme by 
glutamylated MTX results in thymidine depletion and increase in uracil incorporation into DNA, 
which subsequently results in chromosome breaks and cell death [Allegra et al., 1985; Krajinovic 
et al., 2002]. Different polymorphisms in corresponding genes have been described and are 
associated with different TS expression: a double (2R) or triple (3R) 28-bp repeat sequence in the 
enhancer element of the 5´UTR gene region, a G to C substitution of the 3R allele and a 6-bp 
variation in the 3´UTR [Krajinovic et al., 2002]. Children diagnosed with ALL (n = 200) treated 
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according to the DFCI treatment protocol and who are homozygous for the 3R allele, associated 
with higher TS expression, have been shown to have a poorer event free survival (EFS) compared 
to patients without this genotype [Costea et al., 2006].  
B.2.3. Combination of polymorphisms that influence pharmacokinetics and 
pharmacodynamics 
Warfarin is used for the prophylaxis and treatment of thromboembolic diseases [Hirsch et al., 
1998]. The effectiveness and safety of warfarin is critically dependent on maintaining the 
prothrombin time, expressed as the international normalized ratio (INR), within the therapeutic 
range. Therapy with warfarin is complicated by the large interindividual variability in the dose 
required for proper anticoagulation [Cannegieter et al., 1995]. 
Two important candidate genes are associated with the response to warfarin, epoxy reductase 
complex vitamin K 1 (VKORC1) and cytochrome P4502C9 (CYP2C9). The enzyme CYP2C9 
metabolizes the active S-enantiomer of warfarin. The VKORC1 is the target protein of warfarin. 
Specifically, warfarin inhibits VKORC1 and thus prevents the conversion of vitamin K to its 
reduced form, a cofactor necessary for the activation of coagulation factors. CYP2C9 alleles * 2 
and * 3 are the main dysfunctional alleles among Europeans with a frequency of 13% and 6%, 
respectively. Compared to individuals homozygous for CYP2C9 * 1, individuals treated with 
warfarin having one or two copies of CYP2C9 * 2 or * 3 have a high risk of bleeding and need 
more time to acquire a stable INR if treated with standard doses warfarin. Holders of CYP2C9 * 
2 or * 3 alleles require lower doses to achieve similar levels of anticoagulation than individuals 
carrying the CYP2C9 * 1 * 1 [Sconce et al., 2005]. A polymorphism in the regulatory region of 
VKORC1, (G-1639A), has also been identified in order to improve the prediction of the warfarin 
dose to be used. The minor allele A in this position is associated with decreased gene expression 
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and a significant decrease in the dose of warfarin required for anticoagulation compared to the 
major allele G [D’Andrea et al., 2005]. 
Candidate gene studies analyzing these two genes together show that CYP2C9 and VKORC1 
genotypes explain up to 45% of the variability in warfarin dose [Yin and Miyata, 2007]. 
These associations were also confirmed by several genome-wide studies [Takeuchi et al., 2009; 
Perera et al., 2013; Parra et al., 2015]. 
Recognition of the importance of polymorphisms CYP2C9 / VKORC1 led the FDA to change the 
label of warfarin to include the statement that the information of the patient's genotype can be 
helpful for dose adjustment [Gage and Lesko, 2008]. 
B.2.4. Genetic Polymorphisms with Indirect Effects on Drug Response 
Polymorphisms in genes encoding proteins that are neither direct targets of medications nor 
involved in their disposition have been shown to alter the response to treatment in certain 
situations. This approach aligns with the hypothesis of our study, considering that our goal was to 
show that polymorphisms in genes associated with neutropenia may worsen neutropenia caused 
by chemotherapy.  
Similarly, inherited differences in coagulation factors can predispose women taking oral 
contraceptives to venous thromboembolism (VTE). It has been discovered that the molecular basis 
of resistance to activated protein C is G1691A variation in the Factor V gene. This polymorphism 
determines the substitution Arg506Gln of the factor V protein. The mutant protein, called factor 
V Leiden, is less susceptible to inactivation by activated    protein C. FV Leiden is more frequent 
among patients with thromboembolism and confers a 5 to 7 fold increase in risk of VTE [Koster 
et al., 1994]. 
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The risk of venous thrombosis of the lower extremities is increased by factors that cause 
hypercoagulability or venous stasis, such as the use of oral contraceptives. In women who use oral 
contraceptives and have factor V Leiden, risk of VTE is increased 20 to 30 times [Martinelli et al., 
2003]. 
 
B.3. Genetic variants 
Humans are 99.8% identical at the DNA level. This 0.2% variation, could explain the molecular 
basis of differences between individuals. Some of these variations are expressed at the phenotypic 
level (morphology, physiology, behavior, etc.), whereas others remain "hidden", and highlighting 
these variations requires the use of appropriate techniques (variability proteins or sequences 
DNA). Single Nucleotide Polymorphisms (SNPs) are the most studied variants in 
pharmacogenetics, constituting about 90% of all human genome variations and occurring every 
100 to 300 bp.  SNP is defined as a variant found in more than 1 % of the population. SNPs can 
be classified as structural RNA polymorphisms (srSNPs), regulatory polymorphisms (rSNPs), or 
polymorphisms in coding regions (cSNPs): srSNPs alter mRNA processing and translation, rSNPs 
alter transcription, and cSNPs alter protein sequence and function. 
 
B.4. Association studies  
Genetic association studies aim to detect association between one or more genetic polymorphisms 
and a trait. A detected polymorphism could have a causal role, or if no causal role exists the 
polymorphism may be associated with a nearby causal variant; or the association is due to some 
underlying stratification or admixture of the population [Cordell and Clayton, 2005]. 
Direct association studies target polymorphisms which are assumed to be causal variants. This 
type of study is the easiest to analyse and the most powerful, but the difficulty is the identification 
of candidate polymorphisms. A mutation in a codon which leads to an amino acid change is a 
candidate causal variant. However, it is likely that many causal variants responsible for heritability 
of common complex disorders will be non-coding. For example, such variants may cause variation 
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in gene regulation and expression, or differential splicing. We do not know enough to predict 
which variants may have such effects. Thus, direct association studies only have the potential to 
discover some of the genetic causes of disease and disease-related traits [Cordele and Clayton, 
2005]. 
In indirect association studies, the polymorphism is a surrogate for the causal locus and it is 
selected on the basis of linkage disequilibrium (LD). Linkage disequilibrium is the non-random 
association of alleles at different loci i.e. the presence of statistical associations between alleles at 
different loci that are different from what would be expected if alleles were independently, 
randomly sampled based on their individual allele frequencies. These studies have shown that most 
of the common SNPs in the genome have groups of neighbors that are all nearly perfectly 
correlated with each other. The genotype of one SNP perfectly predicts those of correlated 
neighboring SNPs. One SNP can thereby serve as a proxy for many others in an association screen.  
The genes that underlie common disease and quantitative traits may be mapped by two main 
approaches: Genome Wide studies and Candidate Gene studies.  
B.4.1. The genome wide association study (GWAS) 
The genome-wide association approach is an association study that screen most of the genome for 
causal genetic variants. A large number of SNPs across the whole genome may be screened in 
search for disease susceptibility genes. This study represents an unbiased approach, because it may 
be performed even in the absence of convincing evidence regarding the function or location of the 
causal genes [Horschhorh and Daly, 2005]. Genome-wide association studies (GWASs) have 
identified large numbers of loci that contribute to the genetic basis of complex traits, but in almost 
all cases account for only a small fraction of observed heritability of the trait under study [Schork 
et al., 2009]. GWASs are expensive and require great effort to genotype hundreds of thousands of 
SNPs per individual enrolled in the study. 
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B.4.2. Candidate gene study 
Association studies with candidate genes have been widely used for the study of complex diseases. 
The candidate-gene approach can be defined as the study of the genetic influences on a complex 
trait by identifying candidate genes that might have a role in the etiology of the disease; or 
identifying variants in or near those genes that might either cause a change in the protein or its 
expression, or be in linkage disequilibrium with functional changes [Tabor et al., 2002]. 
Furthermore, a candidate-gene study is usually conducted in a population-based sample of affected 
and unaffected individuals (a case–control study). A candidate-gene study therefore takes 
advantage of both the increased statistical efficiency of association analysis of complex diseases 
and the biological understanding of the phenotype, tissues, genes and proteins that are likely to be 
involved in the disease.  
 
B.5. Genotyping  
An allele specific oligonucleotide (ASO) hybridization was performed as a method of genotyping 
in our analysis.  This technique is coupled with Polymerase Chain Reaction (PCR). PCR enabled 
us to amplify a specific target region on the DNA strand. The PCR product is then transferred on 
the membranes. Following cross-linking and denaturation of the amplified DNA, the hybridization 
steps can follow.  
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Figure B. Allele Specific Oligonucleotide Hybridization. 
Oligoprobes for wild type and mutation under investigation are usually designed to be 120bp long. 
The ASO is labelled before hybridization using radioactive isotope of phosphorus ³²P. Membranes 
are placed on photographic film for a few hours, and later exposed. By comparing the presence of 
signal on both films, the genotype for certain loci may be determined [Labuda et al., 1999]. 
 
C. Neutropenia 
C.1. Introduction to neutropenia 
Neutrophils (neutrophilic granulocytes or polymorphonuclear leukocytes) are the most abundant 
white blood cells (>70%), and act as first defenders against infection [Von Vietinghoft and Ley, 
2008]. They play a crucial role against bacterial and fungal pathogens, and participate in the 
development of the inflammatory reaction [Nathan, 2006].  
Their main function is to phagocytize and kill pathogens, while also producing various 
inflammatory mediators.  
Neutrophils are rapidly produced in the bone marrow but after entering the peripheral blood they 
have a half-time of only 6 to 8 hours, and usually die performing their antimicrobial function. Also, 
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neutrophils release cytokines and contribute to orchestrating the immune response [Bazzoni et al., 
1991]. 
Neutrophils are the first to be recruited to a site of infection or a diseased site. Among various 
inflammatory mediators, CXC chemokines including IL-8 (CXCL8), MIP-2 (CXCL2), and KC 
(CXCL1) are the most critical for such recruitment. Neutrophils function as effector cells that kill 
bacteria or destroy affected tissues mainly through the production of reactive oxygen species. 
Recent studies, however, revealed that neutrophils are involved in the production of chemokines 
in response to a variety of stimulants including LPS, TNF-alpha, and IFN-gamma, thereby 
contributing to immunomodulation. These functions are also regulated by selectins during 
infiltration into various sites [Kobayashi, 2008]. 
Neutrophil homeostasis in the blood is achieved through a balance of neutrophil production, 
release from bone marrow and clearance from circulation.  
Neutropenia is defined as an abnormally low number of circulating neutrophils in the peripheral 
blood. According to Common Terminology Criteria for Adverse Events (CTCAE), neutropenia is 
classified from Grade 1 through 4. The absolute neutrophil counts (ANC) below 500 cells/µL are 
categorised as grade 4, between 500 and 1000 as grade 3, between 1000 and 1500 as grade 2, and 
the least severe – between 1500 and 2000 cells//µL –as grade 1.  
Febrile neutropenia is characterized by an ANC<1000/µL and fever of unknown origin without 
clinically or microbiologically documented infection (≥38.3°C). Fever may be the only clinical 
sign of bacteremia, which then may progress to septicemia with a potentially fatal outcome. 
Patients with leukemia often present with neutropenia. The factors that impact the risk of 
developing chemotherapy- induced neutropenia include host genetic, their primary disease –
leukemia and treatment related factors. 
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C.2. Chemotherapy-induced neutropenia and infection 
Febrile neutropenia and infection are the common cause of hospitalisation for pediatric leukemia 
patients. Also, they are major dose-limiting side effect of chemotherapy in malignant disease 
patients [Crawford et al., 1991].  
The degree and duration of neutropenia is determined by the intensity of the chemotherapy 
regiment Current standard therapy for patients with fever in association with neutropenia includes 
hospitalization and immediate use of broad-spectrum intravenous antibiotics [Nijhuis et al., 2002]. 
Because fever may be the first and only manifestation of infection, it has been standard practice 
for all patients who present with fever in the setting of neutropenia to receive broad-spectrum 
antibiotics. Usually this has been accompanied by hospitalization, although certain favorable 
subgroups of patients may possibly be treated as outpatients. Traditionally, patients have remained 
hospitalized, on antibiotic therapy, until fever and any sign of active infection have resolved and 
the ANC has recovered. 
Increased susceptibility to chemotherapeutic agents through prolonged neutropenia represents a 
dose-limiting factor in the proper administration of the chemotherapy regimen. 24% of patients 
treated on the Dana-Farber Cancer Institute ALL Consortium 05-01 required reduction of 6-
MP/MTX administrations during consolidation due to leukopenia and neutropenia [Merryman et 
al., 2012].  
Furthermore, frequent reductions in chemotherapy dose intensity may compromise disease control 
and survival [Lyman, 2009].  
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A prolonged episode of neutropenia is also associated with increased risk of infectious 
complications [Palazzi, 2011]. Infections are the most common treatment related mortality (TRM) 
among pediatric patients with ALL [O'Connor et al., 2014].  
Bacteremia occurs in approximately 10-20% of febrile neutropenic patients aggressively treated 
for acute leukemia [Castagnola et al., 2007]. 
 Bacteria commonly associated with infection in these patients include Streptococcus pyogenes, S. 
pneumonia, Staphylococcus aureus, S epidermidis, viridians streptococci, enterococci, 
Enterobacteriaceae and Pseudomonas aeruginosa. 
Candida species are the most common pathogens causing invasive fungal infection in febrile 
neutropenic children. Common viral infection in children with ALL are caused by influenza, 
herpes simplex and herpes zoster virus. 
More than 40 years ago Bodey et al showed a direct correlation between the duration of 
neutropenia and the risk of infection in patients undergoing chemotherapy for acute leukemia. 
They reported that the most important factor for the increased risk is an absolute neutrophil count 
ANC <0.5x109/L [Bodey et al., 1966].  
The actual risk of severe infection and the likelihood of recovery depend not only on the level of 
the ANC, but on the duration of the neutropenia. There are many factors predisposing to infections 
in these patients, including malignant processes and deficiencies in host defense mechanisms 
secondary to cancer chemotherapy [Bodey, 1986].  
Genetic differences in production of cytokines and other components of the innate immune 
response are considered to be important host factors in individual variability of the clinical 
response to infection. 
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C.3. Ethnical and racial differences 
Ethnicity is an important contributor to variation in leukocyte and neutrophil count. Asymptomatic 
or benign reductions in neutrophils are observed in individuals of all ethnic backgrounds but may 
be more common in those of African descent. A number of studies have found that total WBC and 
neutrophil count are lower in Africans and those of African ancestry [Rippey, 1967; Haddy et al., 
1999; Kourtis et al., 2005].  
Also, the mean neutrophil count in Arabs is lower than in individuals of European origin [Denic 
et al., 2009]. 
Neutropenia associated with race/ethnicity may affect therapy for cancer or other illnesses. Racial 
and ethnic differences in survival in childhood ALL are reported in various studies, with poorer 
outcomes reported for black children than for white children [Rivera et al., 1993; Kadan-Lottick 
et al., 2003]. 
Outcomes for Hispanic children were intermediate between those of white and black children, 
whereas Asian children had outcomes better than all other racial and ethnic groups (Bhatia et al., 
2002]. 
African American women who had received adjuvant chemotherapy for breast cancer had 
statistically significantly lower WBC counts and longer chemotherapy duration than white women 
[Hershman et al., 2003]. 
 
D. Gene selection 
Neutrophil production, release from bone marrow and clearance from the circulation are tightly 
controlled and regulated processes. Myelopoiesis is regulated by a number of cytokines, 
chemokines, growth factors and their receptors. GWA studies identified SNPs, located in regions 
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encoding some of these components of the immune system, to be associated with WBC and WBC 
subtype counts. 
 
D.1.1. Candidate genes and polymorphisms on chromosome 17q21 
G-CSF is encoded by the CSF3 gene on chromosome 17.  Several genetic polymorphisms on 
chromosome 17q21were recently associated with total WBC and neutrophil count in European 
population. [Soranzo et al., 2009; Crosslin et al., 2012; Nalls et al., 2011].  Several of the identified 
polymorphisms are in ORMDL3-GSDMA region, a known susceptibility locus for childhood 
asthma [Moffatt et al., 2010].  
Regulation of the 17q21 locus and its immunologic relevance have not been well characterized. 
Notably, this locus contains the CSF3 gene, which encodes granulocyte colony stimulating factor 
3, a cytokine controlling the production, differentiation and function of granulocytes. CSF3 is the 
most likely biological candidate in this region responsible for phenotypic variation in WBC count 
[Reiner et al., 2011].  
Soranzo et al. applied a genome–wide meta-analysis and identified 22 loci associated with eight 
hematological parameters in the HaemGen consortium.  This consortium contains 13,943 samples 
from six European population-based studies. Only one common variant (rs17609240), located in 
the region between ORMDL3 and GSDMA genes, was associated with total white blood cell count 
(Tabela) [Soranzo et al., 2009]. 
A GWA analysis, led by Crosslin and coworkers, revealed two SNPs in the GSDMA gene 
(rs3894194 and rs3859192) associated with the WBC count [Crosslin et al., 2012]. 
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In addition, Nalls et al. performed a meta-analysis and identified one SNP rs4794822 linked to the 
WBC count and rs8078723 associated with the neutrophil count. 
D.1.2. G-CSF and its role  
The cytokine granulocyte-colony stimulating factor (G-CSF) is critically involved in 
granulopoiesis by stimulating proliferation, differentiation and survival of neutrophil precursor in 
the bone marrow. Also, G-CSF has an important role in neutrophil release from bone marrow into 
the circulation.  
Neutrophil release and production is regulated by G-CSF in physiological stress such as infection 
and in non-inflammatory conditions. It is assumed that G-GSF is made locally in the bone marrow 
under homeostatic conditions, however cellular sources of this cytokine and regulating factors are 
unknown.  
G-CSF is expressed by numerous different cell types upon stimulation with appropriate 
immunogenic factors such as LPS, IFN-gamma, TNF-alpha. 
Accumulating evidence suggests that neutrophil egress from bone marrow is antagonistically 
regulated by CXC chemokine receptors CXCR2 and CXCR4, which are both expressed on 
neutrophils [Semerad et al., 2002; Eash et al., 2010; Wengner et al., 2008].  
CXCR2 ligand (CXCL2) and CXCR4 ligand (CXCL12) are both constitutively expressed by 
osteoblast and endothelial cells in the bone marrow. The CXCR2/CXCL2 axis promotes release, 
while the CXCR4/CXCL12 axis is a key retention signal for neutrophils in the bone marrow [Eash 
et al., 2010].  
In acute inflammation, G-CSF mobilizes neutrophils into the periphery indirectly by shifting the 
balance between retention (CXCR4/CXCL12) and egress (CXCR2/CXCL2) signals. G-CSF 
reduces the number of osteoblasts which are a major source of CXCL12, while increasing 
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expression of CXCR2 ligands by endothelial cells in the bone marrow [Semerad et al., 2002; 
Wengner et al., 2008].  
A recent study by Kohler and colleagues has shown that G-CSF induces CXCR2 ligand secretion 
through thrombopoietin (Tpo). These investigators determined that G-CSF stimulates Tpo 
expression in the bone marrow, which results in the secretion of CXCR2 ligands (CXCL1 and 
CXCL2) by megakaryocytes and possibly endothelial cells [Kohler et al., 2011]. 
G-CSF and CXCL2 produced locally in the BM and at a distance in the peripheral tissues could 
influence neutrophil release from bone marrow synergistically [Wengner et al., 2008]. 
G-CSF generated peripherally promote neutrophil release from the bone marrow, without effect 
on neutrophil infiltration into tissue.  
D.1.3. ORMDL3 and physiological function 
ORMDL3 (orosomucoid 1-like 3) gene is a member of a gene family that encodes transmembrane 
proteins ORMDL3 anchored in the endoplasmic reticulum (ER) [Hjelmqvist et al., 2002]. 
ORMDL3 is expressed in many tissues, particularly liver and peripheral blood lymphocytes and 
its function is generally unknown. Recent reports suggested the involvement of ORMDL3 on ER-
mediated Ca2+ signaling and facilitation of ER-mediated inflammatory responses [Cantero-
Recasens et al., 2010]. 
Additionally, Miller and colleagues demonstrated that in mice ORMDL3 is an allergen and 
cytokine (IL-4 or IL-13) inducible gene, expressed predominantly in airway epithelial cells. 
Allergens induce a 127-fold increase in ORMDL3 mRNA in bronchial epithelium in WT mice 
[Miller et al., 2012]. 
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D.1.4. GSDMA and its role 
The Gasdermin (GSDM) gene family is composed of four genes, Gasdermin A (GSDMA), 
Gasdermin B (GSDMB), Gasdermin C (GSDMC), and Gasdermin D (GSDMD). 
GSDMA is expressed in the upper gastrointestinal tract but frequently silenced in gastric cancers 
(GCs), and regulates apoptosis of the gastric epithelium.  
Recently it was revealed that risk alleles of SNPs within the 17q21 locus were associated with 
increased ORMDL3 and GSDMA gene expression after stimulation. Children homozygous for four 
risk alleles within the 17q21 locus, showed increased expression for ORMDL3 and GSDMA and 
increased IL-17 secretion [Lluis et al., 2011]. 
 
D.2.1. CXCL2 gene 
The CXCL2 gene encodes CXCL2/GRO β, a macrophage–derived chemotactic cytokine for 
polymorphnuclear leukocytes.  
Reiner et al, identified a novel SNP on chromosome 4q13 associated with WBC through a GWA 
study in African Americans. The lead SNP rs9131 is located in the 3’ UTR of the CXCL2 gene. 
The results were replicated in a European cohort confirming association with lower WBC for 
individuals with T allele of rs9131 (P=0.004). Additionally, another SNP rs16850408 showed 
stronger association with WBC signal (P=8.04 ×10-6) than rs9131. This SNP is located in an 
intergenic region between CXCL2 and the pro-platelet basic protein-like 2 gene (PPBL2) [Reiner 
et al., 2011]. 
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D.2.2. CXCL2 and its role  
Neutrophils are the first to be recruited to a site of infection or a diseased site. Among various 
inflammatory mediators, CXC chemokines including IL-8 (CXCL8), MIP-2 (CXCL2), and KC 
(CXCL1) are the most critical for such recruitment [Kobayashi, 2008] 
Chemokines are generated locally at the site of infection and direct the recruitment of leukocytes 
from the bone marrow into tissues. Approaching the injured site, neutrophils leave the peripheral 
blood and transmigrate into peripheral tissue mainly at the post- capillary venules.  
In human models, chemokines induce neutrophil migration mainly via the activation of the CXC 
chemokine receptor 1 (CXCR1) and CXCR2. Both are 7-transmembrane domain-type proteins 
functionally coupled to G proteins. 
The major hallmark of chemokine mobilization is rapid onset, with response occurring in minutes 
and hours. CXC chemokines are generally selective for neutrophils. CXCL2 is a selective ligand 
for the CXCR2 receptor. This ligand is secreted by monocytes, macrophages, neutrophils, and 
endothelial cells. 
It has been shown that a single i.v. injection of chemokine CXCL2 significantly increases the 
number of neutrophils in the bone marrow sinusoids after only 15 minutes [Burdon et al., 2008].  
In the bone marrow, CXCL2 is produced mainly by endothelial cells, and this process is influenced 
by G-CSF. CXCR2/CXCL2 promote egress of neutrophils from the bone marrow into blood 
[Semerad et al., 2002].  
CXCL2 that is secreted in infected tissue may act locally in the circulation recruiting neutrophils 
from blood, and at distance in the bone marrow. Neutrophils leave peripheral blood and 
transmigrate into peripheral tissue mainly at the postcapillary venules. CXCL2 generated in 
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peripheral tissue, has a dual role, namely to recruit neutrophils locally and to mobilize neutrophils 
systematically. 
 
D.3.1. DARC gene 
Duffy antigen/chemokine receptor (DARC), also known as Fy glycoprotein (FY) or CD234 
(Cluster of Differentiation 234), is a protein that in humans is encoded by the DARC gene.  
Nalls and coworkers reported an association between SNP rs2814778 of DARC and white blood 
cell (WBC) count among African Americans through admixture mapping [Nalls et al., 2011]. 
Lower WBC in African population has been attributed to this variant. 
Polymorphisms in this gene are the basis of the Duffy blood group system. Two SNPs (rs12075 
and rs2812778) determine the Duffy antigen phenotype. 
Fy(a ) and Fy(b) differ at a single amino acid at position 42: glycine in Fy-a and aspartic acid in 
Fy(b) due to the guanine to adenosine substitution at  position 125 (rs12075). 
The genetic basis for the Duffy “null” phenotype is a point mutation (rs2814778) in the erythroid 
specific promoter (a T -> C mutation at position -33 in the GATA box ).  
Individuals with Fy (b) allele who are homozygous for rs2814778 do not express Duffy antigen 
on their red blood cells.  
Further it has been shown that low neutrophil count is predominantly responsible for low WBC. 
Neutrophil count was more strongly associated to the Duffy variant than to ancestry, suggesting 
that the variant itself causes benign ethnic neutropenia. The African, or “null,” form of this variant 
abolishes expression of the “Duffy Antigen Receptor for Chemokines” on red blood cells, perhaps 
altering the concentrations and distribution of chemokines that regulate neutrophil production or 
migration [Reich et al., 2009]. 
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Duffy null individuals, mostly African descents, have lower neutrophil count and worse clinical 
outcomes compared to Europeans descents [Kangelaris et al., 2012].  
This variant is very rare among subjects of Europeans ancestry, however no other polymorphism 
in DARC gene was strongly associated with WBC or neutrophils in Europeans. Although, 
Schnabel et al. performed a GWAS of monocyte chemoattractant protein-1 (MCP-1) in three 
independent cohorts of European descendants and identified the strongest association with rs12075 
variant [Schnabel et al., 2010]. 
D.3.2. DARC and its role 
Duffy blood group system was first reported by Catbush and Mollisson, 1950. The Fy gene that 
encodes Duffy glycoprotein is located in the 1q22-q23 region of chromosome 1. The system 
consists of four alleles, five phenotypes, and five antigens. FYA, FYB, FYBES, and FYBWK are the 
alleles; Fy(a + b −), Fy(a − b +), Fy(a + b +), Fy(a − b + wK), and Fy(a − b −) are the phenotypes, 
and Fya, Fyb, Fy3, Fy5, and Fy6 are the antigens. Fy(a − b −), or Duffy-negative individuals, lack 
the Duffy protein on erythrocytes and are predominantly African and American blacks. They have 
the FYBES allele with a mutation in the promoter region, which abolishes the expression of the 
protein in erythrocytes only. In the few cases of non-black Fy(a − b −) individuals, a nonsense 
mutation prevents the synthesis of gp-Fy. In Fy(a − b + wK) erythrocytes, the Fyb antigen is weakly 
expressed due to a reduced amount of the protein. The Fy5 antigen includes the Rh protein, and 
the Fy6 antigen is defined by a murine monoclonal antibody. Gp-Fy is produced in several cell 
types, including endothelial cells of capillary and postcapillary venules, epithelial cells of kidney 
collecting ducts, and lung alveoli, as well as Purkinje cells of the cerebellum [Pogo and Chaudhuri, 
2000].  
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In 1991, Darbonne et al, discovered that Duffy antigen on red blood cells (RBC) binds members 
of the CXC and CC cytokine families with high affinity and it has been subsequently named Duffy 
antigen receptor for chemokines (DARC) [Darbonne et al., 1991]. 
The DARC is expressed mainly on erythrocytes and endothelial cells of the postcapillary venules, 
but also has been found on Purkinje cells in cerebellum, lung alveoli and epithelial cells of kidney.  
DARC belongs to the family of rhodopsin-like seven-helix transmembrane proteins. Unlike all 
other seven-transmembrane chemokine receptors, DARC lacks the highly conserved G-protein 
coupling motif located in the second cytoplasmic loop, and it cannot couple with G-protein and 
transduce subsequent signaling cascades. Thus, it belongs to ‘silent’ receptors known as 
interceptors (internalizing receptors). 
Pruenster and Rot suggest that DARC on erythrocytes acts as a sink and a long-term blood 
reservoir for chemokines. This limits their dissemination through blood into distant tissues and 
organs, and prevents desensitization and activation of plasma leukocytes [Colditz et al., 2007].   
DARC on erythrocytes serves also as a receptor for malaria parasites. Plasmodium vivax (P. vivax) 
and Plasmodium falciparum (P. falciparum) are the most prevalent species of human malaria. The 
P. vivax is primarily dependent on Duffy antigen to invade RBC, where P. falciparum enters 
through multiple receptor pathways.  
The FY(ES) allele with mutation (rs2814778) in the promoter region  results in lack of DARC on 
erythrocytes and subsequent resistance against P. vivax malaria. The Duffy-negative phenotype is 
highly prevalent in individuals of African ancestry, and this phenomenon is explained as an 
evolutionary advantage against malaria for populations with a long history of the disease.   
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Nalls and coworkers reported an association between SNP rs2814778 and low WBC count among 
African Americans [Nalls et al., 2011]. This variant is very rare among subjects of European 
ancestry.  
The African or “null” form of this variant abolishes expression of DARC on red blood cells, 
perhaps altering the concentration and distribution of chemokines that regulate neutrophil 
production or migration. 
Duffy negative individuals lacking erythrocyte receptor still express DARC on endothelial cells 
(EC). DARC on EC supports promigratory function of chemokines, where it acts as an 
unidirectional transporter. Chemokines transported by DARC from the basal to the luminal side 
of EC can be presented to the adherent leukocytes. This could lead to firm adhesion of the 
leukocytes and their subsequent emigration [Pruenster et al., 2009]. 
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CHAPTER 2: HYPOTHESIS AND OBJECTIVES 
 
White blood cell and neutrophil counts can be influenced by individual genetic factors. Recent 
publications provided evidence that genetic variants in DARC gene, ORMDL3-GSDMA-CSF3 
locus on chromosome 17q21 (chr17q21), and CXCL2 gene influence total white blood cell and 
neutrophil count.   These polymorphisms could impact the susceptibility to neutropenia and its 
complications in children undergoing chemotherapy.  
Our objectives were to determine if SNPs in candidate genes influence: 
 toxicity of chemotherapy, defined as the need to postpone the treatment due to 
severe myelosuppression; 
 severity and the frequency of infectious complications during treatment 
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Abstract 
Neutropenia and infection are major dose-limiting side effects of chemotherapy. The risk of initial 
infection and subsequent complications are directly related to the depth and duration of 
neutropenia. Recent publications provided evidences that genetic variants in DARC gene, 
ORMDL3-GSDMA-CSF3 locus on chromosome 17q21 (chr17q21), and CXCL2 gene influence 
total white blood cell (WBC) and neutrophil count irrespective of the treatment.  It is possible that 
polymorphisms of these loci when associated with chemotherapy may put susceptible individuals 
at higher risk of chemotherapy complications.  To test this we investigated the influence of 12 
tagSNPs in DARC gene, 8 SNPs in chr17q21 locus and 2 SNPs in CXCL2 gene on neutropenic 
and infectious complications during chemotherapy in 286 Caucasian children with acute 
lymphoblastic leukemia (ALL). After correction for multiple testing, DARC polymorphism 
rs3027012 in 5’UTR was associated with low absolute phagocyte count (APC<500 and <1000 
cells/µL, p=0.001 and p=0.0005, respectively) and hospitalisation due to febrile neutropenia 
(p=0.004) and hospitalisation due to infection or FN, or both (p=0.007) Protective effect was 
instead noted for missense Gly42Asp variant rs12075 (p=0.006). The polymorphisms on 
chromosome 17q2 were associated with hospitalisation due to infection (rs3859192, p= 0.004) and 
neutropenia (rs17609240, p=0.006, Infection was also modulated by CXCL2 (rs16850408, 
p=0.008).  This study identifies for the first time that the loci modulating WBC and neutrophil 
count may play a role in   the onset of chemotherapy complications and may thus serve as markers 
for adjustment or follow-up of the treatment.  
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Introduction 
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy accounting for 
more than 26% of paediatric cancer cases. The implementation of multi-agent treatment protocol 
has increased remarkably prognosis of children with ALL [Pui et al., 2012]. Despite this 
improvement, treatment-related toxicity remains unacceptably high. Chemotherapy-induced 
neutropenia is the most common hematological toxicity in children with ALL, febrile neutropenia 
(FN) and infection are frequent cause of hospitalisation and the infection is the major factor 
contributing to treatment related mortality [O’Connor et al., 2014]. Increased susceptibility to 
chemotherapeutic agents through prolonged neutropenia represents a dose-limiting factor in the 
administration of chemotherapy regimens; 24% of patients treated on the Dana-Farber Cancer 
Institute (DFCI) ALL Consortium 05-01 protocol required reduction of 6-MP/MTX administration 
during consolidation due to leukopenia and neutropenia [Merryman, 2012]. Furthermore, frequent 
reductions in chemotherapy dose intensity may compromise disease control and survival [Lyman, 
2009], whereas longer duration of neutropenia leads to the increased risk of infection. [Palazzi, 
2011]. Severity of neutropenia can be influenced by a variety of factors, including chemotherapy 
regimen. White blood cell (WBC) and absolute neutrophil counts (ANC) can also be influenced 
by individual genetic factors. Lower counts are commonly observed in certain ethnic groups, in 
particular African-American descents [Rippey, 1967; Haddy et al., 1999; Kourtis et al., 2005] and 
to a lower extent in Arabic peninsula populations [Denic et al., 2009]. Single nucleotide 
polymorphisms (SNP) in the Duffy antigen receptor for chemokine (DARC) were the first to be 
associated with lower WBC, ANC and monocyte count [Nalls et al., 2008]. DARC rs2814778 
SNP, which influences the expression of the Duffy antigen, has been linked to neutropenia in 
African-Americans [Reiner et al., 2011; Crosslin et al., 2012]. By abolishing the Duffy expression, 
the concentrations and distribution of chemokines in the blood and tissues are altered, which may 
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explain the association of this variation with response to infections or to the development and 
severity of certain inflammatory conditions [Kangelaris et al., 2012]. While the DARC rs2814778 
SNP is rare in other ethnic groups, a recent genome wide association study (GWAS) [Reiner et al., 
2011] identified SNPs   linked to the lower WBC and ANC across  different populations in the 
CXCL2 gene, a chemokine implicated in neutrophil mobilisation and recruitment through 
granulocyte-colony stimulating factor (GCSF or CSF-3). Interestingly, SNPs in the ORMDL3-
GSDMA-CSF3 locus, were linked to lower WBC in Europeans [Soranzo et al., 2009; Nalls et al., 
2011; Crosslin et al., 2012]. 
In the present study, we  sought to investigate whether the polymorphisms in ORMDL3-GSDMA-
CSF3 as well as in DARC  and CXCL2 genes due to their impact on WBC and ANC  may 
predispose childhood ALL patients to higher risk of  chemotherapy- related neutropenia and 
infection.  
 
Methodology 
Patient population 
The study population was same as reported previously [Tanfous et al., 2015] and consisted of 286 
Caucasian children diagnosed with ALL at the  Sainte-Justine University Hospital Center (UHC), 
Montreal between January 1989 and July 2005. The consecutively accrued patients for whom DNA 
and clinical data were available underwent treatment with the DFCI ALL Consortium protocols 
DFCI 87-01, 91-01, 95-01, or 00-01 [Silverman et al., 2010]. The study is approved by Ethics 
Committee of Sainte Justine UHC and all participants signed informed consent prior the 
enrollment to the study.  
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SNPs selection 
SNPs in the DARC and CSF3 gene were selected from the 1000 Genomes database 
[http://1000genomes.org] 17 based on their minor allele frequency (MAF) in a Caucasians. The 
tagging variants (tagSNPs) were then selected by pairwise linkage disequilibrium r² statistics  
[Carlson et al., 2004] implemented in Haploview  among SNPs with MAF ≥ 5% located in coding 
and regulatory gene regions spanning ~2kB upstream and downstream of the gene. Twelve tag 
SNPs were identified in the DARC gene and 5 such SNPs were retained in the CSF3 gene 
(Supplemental Figure 1a and 1b respectively). Among five polymorphisms associated previously 
with WBC in ORMDL3-GSDMA locus, two (rs4794822 and rs8078723) were in strong LD (r2=1) 
with tag SNP (rs1042658) in CSF3, and three remaining (rs17609240, rs3894194, rs3859192) 
were added to the analysis. Polymorphisms in CXCL2 locus (rs9131 and rs16850498,) due to their 
reported association with WBC, were also analyzed. 11 Genotypes were obtained using genotyping 
platforms at Genome Quebec and McGill Innovation Center or by allele-specific oligonucleotide 
hybridization as previously described [Labuda et al., 1999] (Supplemental Table 1).  
Outcome measures 
Clinical outcomes were defined as neutropenic or infectious complication and included episodes 
of febrile neutropenia, low absolute phagocyte count (APC) that delayed the treatment, high grade 
infections and hospitalisation due to infection and/or neutropenia.  The data were collected during 
consolidation and maintenance treatment through medical chart reviews. The occurrence of these 
episodes (at least one vs. none) and their severity, assessed by the frequency in a total number of 
chemotherapy cycles, or by the length of hospitalisation per total length of treatment, were both 
used in association analysis.   
The absolute phagocyte count (APC) was calculated as the sum of the absolute neutrophil count 
(ANC) and absolute monocyte count (AMC). APC<1000 per µL and APC<500 cells per µL 
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defining the delay in treatment were both used in the analysis. Hospitalization due to FN included 
children with leukemia who present with fever and neutropenia and are hospitalized for parenteral 
antibiotics. Severity of infection was graded using National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE), version 3.0 [http://www.ctep.cancer.gov]. 
Higher grades (grades 3 and 4) were considered; grade 3 assumes infection that requires 
intravenous administration of antibiotics, and grade 4 is infection that causes sepsis or death. 
Hospitalisation due to infection (viral, bacterial, and fungal) was defined based on clinical and/or 
microbiological evidence of infection, but without neutropenia that required hospitalization and 
use of oral or parenteral antibiotics. Hospitalization due to either infection or neutropenia only and 
all hospitalizations due to infections and/or neutropenia combined were recorded and analyzed.  
 
Statistics 
Associations of genotypes with binary clinical outcomes were evaluated using Fisher’s exact test 
(the two-sided). Based on frequency distribution, and for the odds ratio (OR) estimates, the 
genotypes were grouped according to the appropriate genetic model (dominant or recessive in 
relation to minor allele). Mann-Whitney U test was performed to assess an association between 
genotypes and the frequency of neutropenic or infectious complications or with the length of 
hospitalization. Benjamini-Hochberg false discovery rate (FDR) [Benjamini and Hochberg, 1995] 
was used to adjust for multiple testing. The cut off p value, when controlling FDR at 0.1 level, was 
0.009. Multivariate analysis performed by logistic regression included beside genotypes, age, sex, 
risk group, treatment protocol and WBC at diagnosis. 
All analyses were performed by SPSS statistical package (Chicago, IL), version 20.0. 
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Results 
Three polymorphisms in the DARC gene (rs3027012, rs863006 and rs12075) were associated with 
hospitalization due to febrile neutropenia (Table 1).  The minor allele of rs12075 A/G SNP that 
leads to Asp42Gly substitution had protective effect (OR=0.3, 95% CI=0.2-0.7, p=0.006), the 
finding was further supported by an association with shorter hospitalization periods (p=0.002, 
Figure 1a).  Similar effect was noted for rs863006 A/G SNP (p=0.003, Table 1). In contrast, T 
allele of rs3027012 C/T was associated with higher risk of FN-related hospitalization (OR=2.1, 
95% CI=1.3-3.6, p=0.004) and longer hospitalization periods (p=0.004, Figure 1b). Same 
association pattern was seen with APC reduction; rs863006 had protective effect (p=0.007, Table 
1) whereas minor rs3027012 T allele correlated with higher risk of APC below 500 cells/µL 
(OR=2.4, 95% CI=1.5-4.0, p=0.001) and was highly predictive of a reduction of APC below 1000 
cells/µL, (OR=14.4, 95% CI=1.9-108.4, p=0.0005, Table 1). Carriers of this allele had also more 
frequent episodes of APC reduction (p≤0.004) compared to non-carriers (Fig. 1c and Fig 1d). Same 
allele was predictive of hospitalization due to either neutropenia or infection (OR =2.1, 95% 
CI=1.23-3.58, p=0.007) and correlated with the length of these hospitalizations (Fig. 1e, p=0.007).   
Among polymorphisms of the ORMDL3-GSDMA locus and CXCL2 gene that were previously 
associated with WBC [Soranzo et al., 2009; Nalls et al., 2011; Reiner et al., 2011; Crosslin et al., 
2012]. Rs16850408 in the CXCL2 gene region had higher risk of infection (ORAA = 2.4; 95% CI, 
1.2-4.5, p=0.008, Table 1) whereas homozygotes for the minor allele of rs3859192 T/C 
polymorphism in the GSDMA were less likely to be hospitalized due to the infection (OR=0.5; 
95% CI, 0.3-0.8, p= 0.004, Table 1) and had also shorter hospitalization time (p=0.008, Fig. 1f). 
Minor allele for ORMDL3-GSDMA rs17609240 G/T was a risk factor for APC lower than1000 
cells /µL (OR=3.5, 95% CI=1.4-8.5, p=0.006, Table 1). 
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Discussion 
Myelopoiesis is regulated by a number of cytokines, chemokines, growth factors, and their 
receptors. Endothelial DARC facilitates leukocyte recruitment and migration [Pruenster et al., 
2009] a homeostatic role of DARC in chemokine ligand-receptor interactions may affect 
neutrophil release from the bone marrow under both basal and inflammatory conditions. [Colditz 
et al., 2007; Pruenster et al., 2009, Reiner et al., 2011].  The Duffy null state, defined by a functional  
T-46C  polymorphism (rs2814778) in the promoter region of Darc gene, present almost exclusively 
in people of African descent, has been associated with baseline neutropenia, altered chemokine 
levels and increased susceptibility to infections and  inﬂammatory diseases [Kangelaris et al., 
2012; Grann et al., 2008]. The rs12075 A to G missense mutation, leading to Gly42Asp 
replacement, differentiates Duffy Fya and Fyb antigens, and influences monocyte chemoattractant 
protein-1 (MCP-1) levels [Schnabel et al., 2010]. It has been associated with WBC in the subjects 
of African ancestry. The same association was seen in Europeans but with lower effect size; 
Carriers of minor allele had on average a higher median WBC. [Crosslin et al., 2012]. This allele 
was associated in our study with lower risk and shorter hospitalization due to febrile neutropenia 
Similar protective effect was seen for the rs863006 variant, likely due to relatively high LD with  
rs12075 (r2=0.7). The association of rs12075 with IL8 levels, metastatic potential in breast cancer 
patients and the chemokine sequestration ability was also reported [Yang et al., 2015; Yu et al., 
2015; Velasquez et al., 2015]. The most notable effect seen in our study was that of rs3027012 
SNP. The minor T allele was associated with higher risk of hospitalization due to FN, or due to 
infection and neutropenia and higher risk of APC reduction. Almost all patients that were carriers 
of minor T allele had reduction in APC below 1000/ul during at least one chemotherapy cycle. 
There was also an association with the severity of these complications, T allele carriers had higher 
number of cycles with APC reduction and longer hospitalization periods. The rs3027012  is located 
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in the 5’UTR of DARC gene and is predicted to affect several transcription factors including the 
binding site for Nkx5-2 homeodomain transcription factor involved in Wnt signaling [Miller et al., 
2013]; some of the Wnt ligands have been shown to influence neutrophil recruitment and 
inflammation response [Jung et al., 2013]. 
Regarding 17q21 region, our results are in concordance with previous studies. Variant rs17609240 
in ORMDL3-GSDMA locus and missense rs3894194 in GSDMA were associated with WBC at 
the genome-wide significance level [Soranzo et al., 2009, Crosslin et al., 2012] and in our study 
influenced risk of neutropenia and length of hospitalization due to infection.  Rs3894194 was also 
shown to contribute to the risk of childhood asthma [Moffatt et al., 2010]. Association of 
ORMDL3–GSDMA locus with WBC count were thought to be partly related to the proximity of 
CSF3 gene which stimulates proliferation, differentiation, and survival of neutrophil precursors 
[Christopher and Link, 2007].  However, no clear association of CSF3 gene polymorphisms with 
WBC was reported, at least in Europeans. Polymorphisms of CSF3 gene were associated with 
treatment-related complications in our study.   
CXCL2, by binding to CXCR2, promote rapid release of neutrophils from the bone marrow, 
thereby elevating blood neutrophil counts during infection or during CSF-induced neutrophil 
mobilization [Nguyen-Jackson et al., 2010]. The rs16850408 in the CXCL2 locus was associated 
with lower WBC count in Europeans [Reiner et al., 2011] and in our study correlated with the risk 
of high grade infection.  
In conclusion, this study is the first to our knowledge to show that genetic host factors in DARC 
gene and in GSDM-ORMDL3 and CXCL2 loci may influence onset and severity of chemotherapy 
-related neutropenia and infection in children with ALL. It also describes for the first time the 
implication of several DARC gene variants with most notable effect of rs3027012 in the 5’UTR, 
which warrants further attention through functional and replication studies. 
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Table 1. The polymorphisms associated with neutropenic and infectious complications. 
Phenotype 
 
 Polymorphisms Genotype Complications                          
+                   - 
OR (95% CI) 
 
P 
APC<0.5 
DARC CC 78 103 1 - 
rs3027012 C/T CT/TT 68 37 2.42 (1.47-3.98) 0.001 
APC<1 
ORMDL3_GSDMA GG 91 15 1 - 
rs17609240 G/T GT/TT 169 8 3.48 (1.42-8.52) 0.006 
DARC AA/AG 203 14 1 - 
rs863006 A/G GG 29 8 0.25 (0.097-0.65) 0.007 
DARC CC 159 22 1 - 
rs3027012 C/T CT/TT 104 1 14.38 (1.91-108) 0.0005 
F
N
 h
o
sp
it
a
li
sa
ti
o
n
. 
DARC AA/AG 43 52 1 - 
rs863006 A/G GG 42 117 0.43 (0.25-0.74) 0.003 
DARC CC 47 134 1 - 
rs3027012 C/T CT/TT 45 60 2.13 (1.28-3.56) 0.004 
DARC AA/AG 24 18 1 - 
rs12075 A/G GG 24 54 0.33 (0.15-0.72) 0.006 
Combined
hospit. 
DARC CC 107 74 1 - 
rs3027012 C/T CT/TT 79 26 2.1 (1.23-3.58) 0.007 
Infection 
Grade 3/4 
CXCL2 CC/CA 105 128 1 - 
rs16850408 C/A AA 33 17 2.36 (1.24-4.48 0.008 
Infection 
hospit. 
tion 
GSDMA TT/TC 88 105 1 - 
rs3859192 T/C CC 25 65 0.45 (0.26-0.78) 0.004 
 
Table 1. Statistically significant genetic polymorphisms in DARC, CXCL2 and ORMDL3-
GSDMA region after the adjustment for multiple comparison P-values are determined using 
Fisher exact test. Benjamini-Hochberg method is used to adjust for multiple genetic variants. The 
p-value cut-off, when controlling FDR at 0.1 level, was p=0.009. 
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Figure legend 
Figure 1. The polymorphism in DARC and GSDMA genes in relation to the frequency of 
neutropenia and duration of hospitalization. 
The frequency mean and average length of hospitalization with 95% CI are given for individuals 
with and without indicated genotypes.  P value for the difference between groups, obtained by 
Mann-Whitney U test is indicated on the plots. APC, absolute phagocyte count, FN, febrile 
neutropenia. 
 
Supplementary Figure 1. Genomic structure and selected tag SNPs of neutropenia pathway 
genes. 
Exonic and coding sequence of DARC in a), CSF3 in b), ORMDL3-GSDMA locus in c), and 
CXCL2 in d) are presented by open and gray boxes respectively. Tag SNP are presented by 
shaded gray dots, SNPs id (rs number from dbSNP database) and MAF, is given in parenthesis. 
SNP in linkage disequilibrium LD are presented by A*. The tick black and gray arrow indicate 
the transcription (TSS) and translation start (ATG) sites, respectively. 
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Figure 1. 
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Supplementary Figure 1. 
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Supplementary material 
Supplementary Table 1. Identity of polymorphisms, details of PCR and ASO hybridization. 
Polymorphisms 
PCR primers ASO probes 
Gene SNP 
CSF3 
rs2227325 
F:AGCTAAGGGGGATGGAACTG aC:GACAGTGCTCGGGAGG 
R:CCCCCACTCTCTGATCTCAC dT:GACAGTGCTTGGGAGG 
rs2227316 
F:CACCTACTTGGGAGGCTGAG aC:CCCACCCTCTACTCC 
R:GTGGATGTGGTGACTGGATG dT:CCCACTCTCTACTCC 
GSDMA 
rs3859192 
F:CGCCCTACCCCTGACATTAT aT:CAGAGACTGGAAGG 
R:TCGGGAACACACTCAGTCTC dC:CAGAGACCGGAAGG 
rs3894194 
F:GTAAACTCTCTCTGCAGGGG aA:GCTAAACCCTCAAGGGGACCTG 
R:TGTCAAGTGGTGTCAGGTC dG:GCTAAACCCTCGAGGGGACCTG 
ORMDL3
-GSDMA 
rs17609240 
F:GCCCTGATACCAAGCTACAA aG:CCTTCCGCCAAGG 
R:CAGGAGAGGATGAGAGGAGA dT:CCTTCCTCCAAGG 
DARC 
rs13962 
F:GGGTCCAGAAGAGAGGGAAAC aG:GTCCTGGCACAGCTG 
R:CTCAGTTGAGGGGGAGAGCTC dA:GTCCTGACACAGCTG 
rs7550207 
F:GTCCCTTATCCCTATGCCCC aT:CCTTCCTGCTTTTTTC 
R:AAAGGGAGGGACACAAGAGG dC:CCTTCCCGCTTTTTTC 
rs3027012 
F:AGCTAGACACACCCAGACAC aC:CAGCAAACGTACACAG 
R:GGTCAACTCTGTCCCAACTG dT:CAGCAAATGTACACAG 
rs863003 
F:AGATGTTCTCTTGAGGTGTGG aA:GGGAGTCATTAAACC 
R:AGTTCCTATTCCATTTGCTTCCC dG:GGGAGTCGTTAAACC 
CXCL2 
rs9131 
F:ACCCAAGTTAGTTCAATCCTGA aG:GGCCAGTGAGATC 
R:CACACATACATTTCCCTGCC dA:GGCCAGTAAGATC 
rs16850408 
F:AGTCCAGTTGAACAATGCTT aC:CAAAGCAAAACAGA 
R:TGGATAGATTGTGTCACCATGA dA:CAAAGAAAAACAGA 
 
Supplementary Table 1. R, reverse, F, forward. The base substitution that distinguishes the two 
variants of each polymorphism is given in bold for ASO probes. dbSNP number is provided. 
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Ancestral allele is given in bold and minor allele is underlined. The polymorphism is presented 
as a change from ancestral to derived allele. SNPs in coding region leading to amino-acid 
substitutions are indicated. 
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CHAPTER 4: DISCUSSION 
 
The immune system is very complex. The defence against infection is shaped by the contributions 
of multiple genes and environmental factors. Research of the genetics behind immune response 
and infective disease may have future implications on therapeutic targets. 
Our objective was to identify genetic polymorphisms determining leukocyte count that predispose 
to hematological toxicity and infection. Such research provides a deeper understanding of immune 
behavior and immune response, especially for patients under myelosuppression treatment and 
susceptible to neutropenia.  
In our study, twelve tagging SNPs in the DARC gene were selected and genotyped. We obtained 
the most significant results for three polymorphisms (rs12075, rs3027012 and rs863006). These 
polymorphisms were not previously detected, possibly due to different sample size or phenotype 
selection [Crosslin et al., 2012; Reiner et al., 2011; Nalls et al., 2011]. Generally, total WBC and 
neutrophil count were analyzed. Only one significant SNP (rs2814778) in the individuals of the 
African ancestry was identified in DARC gene. 
Several investigators have observed that African Americans have lower leukocyte and neutrophil 
counts during chemotherapy when compared with white patients [Hershman et al., 2003; 
Kangelaris et al., 2012]. This reduction has been proposed to be one of many reasons for the 
frequent dose modification, treatment delay, and possibly higher cancer-related mortality in 
African Americans. However, no polymorphism in DARC gene has been revealed in the European 
population. 
We have found significant association between low absolute phagocyte count and rs3027012 and 
rs863006. 
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C rs3027012 T was associated with three analyzed outcomes. The presence of T allele was a risk 
for FN-related hospitalisation and low absolute phagocyte count (APC <500 and <1000 cells per 
µL). Particularly, patient carriers of CT/TT genotypes had 14-fold increased risk of APC<1000 per 
µL (p=0.009). In contrast, GG genotype of A rs863006 G polymorphism had protective effect 
against APC<1000 cells per µL. Accordingly, hematotoxic effects could be enhanced among 
patients exposed to chemotherapy who have genetic variants that alter key pathway regulating 
hematopoiesis.  
Although, the Duffy missense mutation rs12075 A/G (Asp42Gly) has been recently shown to 
strongly determine the serum concentration of monocyte chemoattractant protein-1 (MCP-1). 
Individuals with AA genotype had higher MCP-1 concentration in serum than AG/GG [Schnabel 
et al., 2010]. MCP-1 is a member of CC chemokines and is central to the in inflammatory process. 
DARC has a high affinity for CC and CXC cytokines and could significantly impact chemokines 
homeostasis [Colditz, et al., 2007; Pruenster et al., 2009]. 
The genetically determined capacity of DARC to bind chemokines may have significant 
implication because on red blood cells it acts as a reservoir for chemokines and on the endothelial 
cells provide chemokine-mediated recruitment of leukocyte and transendothelial chemokine 
transport. GWA study by Crosslin et al reported small effect size for this SNP and WBC count 
[Crosslin et al, 2012].  
In our study, patients with AA genotype of rs12075 had higher risk of hospitalization due to febrile 
neutropenia and more frequent episodes of this toxicity possibly via an increase in circulating 
MCP-1. In one study, performed by El-Maghraby SM and colleagues, MCP-1 is identified as 
important risk factor for febrile neutropenia in children with hematologic malignancies. They 
determined that low levels of MCP-1, IL-8 and CRP, could identify patients with unexplainable 
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fever; whereas, high levels of these markers were of help in the diagnosis of infectious episodes 
[El-Maghraby et al., 2007].  
Identification of the polymorphisms influencing MCP-1, IL-8 and CRP would explain variability 
in their concentration and role in inflammatory processes. Influence of rs12075 polymorphism on 
the efficacy of chemotherapy in childhood ALL, defined as EFS and OS, remains to be studied.  
There was a genome-wide significant association with WBC for subjects of European ancestry on 
the 17q21.1 region. There were several genes tagged by the genome wide significant SNPs located 
in this region. Our results regarding 17q21 region provided further evidence that these loci may 
play a role in regulating inflammatory processes and disorders. We replicated results for two 
variants out of five selected near ORMDL3 and GSDMA genes. Genetic variant rs17609240 near 
ORMDL3 gene was associated with WBC of genome-wide significance in the HaemGen 
consortium [Soranzo et al., 2009]. In our analysis, variant allele T of rs17609240 contributed to 
higher risk of APC<1000 cells per µL. The functional significance of this SNP is not known and 
should be further elucidated. This SNP is located in the region between ORMDL3 and GSDMA. 
ORMDL3 gene encodes orosomucoid 1-like protein 3 localized to the endoplasmic reticulum 
membrane. This gene is a promising candidate for asthma in whites [Moffatt et al., 2010]. 
Recent reports suggested the involvement of ORMDL3 on ER-mediated Ca2+ signaling and 
facilitation of ER-mediated inflammatory responses [Cantero-Recasens et al., 2010]. Additionally, 
Miller and colleagues demonstrated that in mice ORMDL3 is an allergen and cytokine (IL-4 or 
IL-13) inducible gene, expressed predominantly in airway epithelial cells. Allergens induce a 127-
fold increase in ORMDL3 mRNA in bronchial epithelium in WT mice [Miller et al., 2012]. 
Rs17609240 could be in the linkage disequilibrium with polymorphisms influencing ORMDL3 
protein that could have role in inflammation.  
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In this region we analyzed also two GSDMA variants. Crosslin and coworkers identified these 
variants to be associated with WBC count in whites. Interestingly, these SNPs (rs3859192 and 
rs3894194) were previously found to contribute to the risk of childhood asthma [Moffatt et al., 
2007].  
GSDMA is expressed in the upper gastrointestinal tract but frequently silenced in gastric cancers 
(GCs), and regulates apoptosis of the gastric epithelium [Saeki et al., 2008]. 
Recently, it has been revealed that risk alleles of SNPs within the 17q21 locus were associated 
with increased ORMDL3 and GSDMA gene expression after stimulation. On the basis of LD 
analyses, 4 major LD blocks were identified, each represented by a tagging SNP (rs7216389, 
rs4795405, rs8079416, rs3859192). Children homozygous for four risk alleles within 17q21 locus, 
showed increased expression for ORMDL3 and GSDMA and increased IL-17 secretion (Lluis et 
al., 2011). Homozygotes for T allele of rs3859192 T/C were associated with increased expression 
for GSDMA.  
According to our results, the polymorphism rs3859192 T/C, intronic variant of GSDMA gene, has 
been linked to higher risk of infection-related hospitalisation. Individuals with the CC genotype 
had lower frequency of hospitalization compared to T allele carriers.  
The second SNP within GSDMA gene (rs8079416) was in LD with rs3894194, however we didn’t 
replicate this polymorphism analyzing it in our study population. Relation between ORMDL3-
GSDMA locus and infection should attract researcher attention and should be elucidated. Notably, 
17q21 region contains CSF3, which encodes granulocyte colony stimulating factor 3, a cytokine 
controlling the production, differentiation and function of granulocytes. CSF3 is a logical 
candidate for this study due to its biological function. Animal studies have documented that CSF3 
plays a key role in regulation of neutrophil homeostasis. Dogs depleted of CSF3 developed 
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profound neutropenia [Hammond et al., 1991]. Additionally, CSF3 knockout mice display chronic 
neutropenia [Liesche, 1994].  
The polymorphisms on chromosome 17 (ORMDL3-GSDMA-CSF3) were linked to asthma and as 
we have shown, with infections. The mechanism underlying this phenomenon could be universal, 
systematic, or it could be the consequence of different pathways.  
It has been shown that G-CSF and CXCL2 produced locally in the bone marrow and at distance 
in the peripheral tissues, could influence neutrophil release from bone marrow synergistically 
(Wengner et al., 2008).  The CXCL2 gene encodes the chemotactic cytokine CXCL2. During 
infection, CXCL2 binds to CXCR2 providing rapid release of neutrophils from bone marrow, and 
its subsequent migration into the site of infection. 
The polymorphisms in CXCL2 gene were recently found to be associated with WBC count in 
Africans, Europeans, Hispanics and Japanese (Reiner et al., 2011). 
SNPs rs9131 and rs16850408 located in the CXCL2 region of chromosome 4 were associated with 
lower WBC count in Europeans.  
CXCL2 binds to CXCR2 receptor in neutrophils enabling their activation and recruitment. Rare 
genetic variants (MAF=1%) in CXCR2 gene were detected and CXCR2 gene remains interesting 
for further analysis. 
In conclusion, genetic factors in DARC, CXCL2 and CSF3 genes may influence chemotherapy 
toxicity defined as the presence and the severity of neutropenia and infectious complications in 
children with ALL. 
The demonstration of a relationship between these polymorphisms and influence on the 
chemotherapy toxicity could help to define strategies to better individualize chemotherapy for 
patients at increased risk of toxicity. This may also help to identify those at increased risk of 
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infectious complications. It may have an impact on operating system and the EFS for children 
treated with chemotherapy. A similar analysis can also be performed in other types of 
chemotherapy against pediatric cancer. 
The results of this project contribute in a better understanding of genetic variants associated with 
WBC, ANC and APC as well as ethnic and racial differences in survival for children with acute 
lymphoblastic leukemia. 
This study identifies for the first time that the loci modulating WBC and neutrophil count may 
play a role in   the onset of chemotherapy complications and may thus serve as markers for 
adjustment or follow-up of the treatment. 
Also, the functional significance of these variants and their impact on the mechanisms of infection 
and inflammation remain to be studied. 
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